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This study has compared the efficacy and tolerability of formoterol (FORADIL) dry powder and salbutamol in 
elderly patients with reversible obstructive airways disease (ROAD). A total of 262 elderly outpatients with clinically 
stable ROAD participated in a multicentre, double-blind, parallel study. Patients were randomized in equal numbers 
to receive formoterol 12 ug b.i.d. formotero124 ug b.i.d. or salbutamol400 ug q.i.d. for a 3 month period. All study 
drugs were inhaled through an Aeroliser @ device. Daily morning and evening peak expiratory flow (PEF) values, 
symptom scores and additional bronchodilator use were recorded by the patients throughout the study. Clinic 
assessment which included spirometry and PEF measurements was made at 4,8 and 12 weeks. Morning and evening 
PEF values were significantly higher with both doses of formoterol compared with salbutamol. This difference was 
statistically significant both for the overall study period and during the week preceding each of the clinic visits (4, 8 
and 12 weeks). There was no significant difference for the two doses of formoterol with respect to PEF values. The 
FEV, and FVC values between the three treatment groups were similar. The daily use of rescue medication was 
significantly lower for the formotero124 ug group compared with the salbutamol group. The percentage of patients 
rating the therapeutic effect as ‘very good’ was significantly higher for formoterol: 41% on 12 ug; 34% on 24 ug; 19% 
on salbutamol. All treatments were well tolerated. This study demonstrates that formoterol 12 ug and 24 ug b.i.d. by 
dry powder inhalation are equally effective and are both significantly superior to salbutamol 400 ug q.i.d. in the 
treatment of ROAD in the elderly. 
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Introduction 
The introduction of long-acting /I,-agonists has been an 
important development in the treatment of obstructive 
airway diseases (1). The main advantage over short-acting 
&agonists is their prolonged duration of action of at least 
12 h. Long-acting P,-agonists can be given twice daily and 
provide better control of nocturnal and early morning 
symptoms of asthma. Formoterol is a potent long-acting 
selective &agonist which is both effective and well toler- 
ated in patients with asthma (2). It produces bronchodila- 
tion of rapid onset which lasts for at least 12 h (3-6). 
Formoterol has been developed for inhalation as an aerosol 
from a metered-dose inhaler (MDI) and more recently as a 
dry powder formulation. 
Dry powder delivery systems do not require the patient 
to co-ordinate the actuation of the device with inhalation 
and so are often found by patients to be easier to use than 
MDIs (7). The problems of co-ordination and compliance 
with inhaled therapy may be a particular concern in the 
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elderly. Therefore, in elderly asthmatic patients requiring a 
long-acting &-agonist to control symptoms a twice-daily 
regime administered by a dry powder delivery system may 
be particularly appropriate. However, data on the effects of 
long-acting &agonists in the elderly is relatively limited (8). 
Specific studies in the elderly are necessary to assess both 
tolerability, since this may differ from that in younger 
patients, and efficacy, since the response to /&-agonists may 
decline with age (9). Dose ranging studies with formoterol 
from both an MD1 and a dry powder delivery system have 
demonstrated that 12 ug b.i.d. is the optimal dose in adults 
and children (4,5,10,11). There is a suggestion in some 
studies that elderly patients might derive greater benefit 
from the 24 ng dose. This study, therefore, compares the 
efficacy, tolerability and patient acceptability of two doses 
of formoterol dry powder, 12 ug b.i.d. and 24 ug b.i.d., with 
salbutamol 400 ug q.i.d. over a 3 month period in elderly 
patients with reversible obstructive airways disease 
(ROAD). 
Methods 
PATIENTS 
A total of 262 elderly male and female patients (aged 6482 
years) with ROAD such as asthma or chronic obstructive 
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TABLE 1. Summary of patients’ characteristics 
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Formoterol 12 ug; Formoterol 24 ng; Salbutamol 400 ug; 
n=83 n=91 n=88 
Mean age (years) 
Sex 
Male 
Female 
Smoking 
Smoker 
Non-smoker 
Ex-smoker 
Predicted FEV, (1) 
Observed FEV,, pre-&agonist (1) 
FEV,, post-&-agonist (1) 
71 (64-82) 71 (6479) 70 (65-80) 
70% 56% 55% 
30% 44% 45% 
16% 12% 15% 
25% 22% 28% 
58% 66% 57% 
2.4 (1.3-3.3) 2.3 (1.2-3.6) 2.3 (1.2-3.6) 
1.4 (0.4-3.2) 1.3 (0.5-3.1) 1.3 (0.5-3.2) 
1.7 (043.3) 1.6 (0.6-3.4) 1.6 (0.7-3.3) 
Ranges in parentheses. 
TABLE 2. Comparison of overall mean PEF values between treatments 
Treatment difference estimate 
(1 min-‘) 95% CI 
Morning 
Formoterol 24 ug XS. salbutamol 
Formoterol 12 ug vs. salbutamol 
Formoterol 24 ug vs. formoterol 12 ng 
Evening 
Formoterol 24 pg vs. salbutamol 
Formoterol 12 ug vs. salbutamol 
Formoterol 24 pg vs. formoterol 12 ug 
33.6* 21.046.2 
33.3* 20.346.2 
0.3 - 12.6 to 13.2 
29.7* 18.341.1 
32.3* 20.544.1 
- 2.6 - 14.2 to 9.1 
*p<o.o01. 
pulmonary disease (COPD) with a degree of reversible 
obstruction participated in the study. Patients were 
recruited from hospital outpatient clinics and from general 
practice. 
Patients had to be clinically stable and had to have been 
using inhaled short-acting /3,-agonists for at least 1 month 
prior to the start of the study. At the screening visit the 
FEV, value (forced expiratory volume in 1 s) had to be at 
least 40% of the predicted normal level. Patients were 
required to demonstrate either an improvement of at least 
15% in FEV, 15-30 min after inhalation of a &agonist 
(dose equivalent to 400 ng dry powder or 2.5 mg nebulized 
salbutamol) or a difference between morning and evening 
PEF values (peak expiratory flow) of greater than 15% on 
at least 3 days of a 2 week run-in period prior to randomi- 
zation. All subjects gave written consent to participation in 
the study which was approved by the relevant local Ethics 
Review Boards. 
STUDY DESIGN 
The study was multicentre, double-blind, comparative 
and parallel designed. After the screening visit, all oral 
and inhaled &agonist therapy was discontinued and 
patients were given salbutamol 400 ug q.i.d. administered 
by a dry powder device for a 2 week run-in period. 
Other airway medication remained unchanged. Follow- 
ing the run-in period patients were randomized in equal 
numbers to receive formoterol 12 pg b.i.d., formoterol 
24 ug b.i.d. or salbutamol 400 ug q.i.d. for a 3 month 
period. Treatments were allocated on the basis of a 
randomized code and patients were entered sequentially. 
All medication was administered using a dry powder 
device (Aeroliser@ Italseber Farmaceutici, Italy). 
Patients randomized to formoterol took active treatment 
in the morning and evening. At midday and bedtime a 
placebo capsule containing lactose with an identical 
outward appearance was used. Patients randomized to 
salbutamol took active medication in the morning, at 
midday, in the evening and at bedtime. Each patient was 
provided with a salbutamol (200 pg) Ventolin Rotahaler 
as rescue medication. 
Patients recorded the highest of three PEF values before 
dosing each morning and evening using a Mini-Wright peak 
flow meter. Daytime and night-time asthma symptoms were 
recorded on a diary card daily using a four-point scale 
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FIG. 1. (a) Morning and (b) evening mean PEF values 
during the week before each clinic visit in patients receiv- 
ing formoterol 12 pg (B), formoterol 24 pg (0 or salbuta- 
mol400 pg q.d.s (A). 
(from 0, meaning no symptoms, up to 3, for symptoms 
occurring at rest with no relief afforded by rescue medi- 
cation). Clinical assessments were made at 4, 8, and 12 
weeks of treatment. At these visits FEV, and FVC (forced 
vital capacity) were measured using a dry wedge spirometer 
(Vitalograph, U.K.). PEF measurements, physical examin- 
ation, blood tests (haematological and biochemical) has an 
ECG were also carried out. At the final clinical visit (12 
weeks), an overall assessment of therapeutic effect and 
tolerability was made by the patient and the investigator 
qccording to a four-point scale (poor, fair, good, very 
good). 
STATISTICAL METHODS 
Treatments were compared independently for morning 
and evening PEF values, using analysis of covariance 
(ANCOVA) with baseline PEF value, centre and sex 
included in the analysis. The patient’s mean PEF results for 
the three treatments taken over the entire double-blind 
period were compared without carrying forward data for 
missing days or trimming highest and lowest values. Treat- 
ments were also compared with respect to PEF values 
during the 7 days prior to clinic visits at 4, 8 and 12 weeks. 
In this case, final observations were carried over for missing 
data and the trimmed mean was used if data were available 
for at least 3 days. The patient’s mean daily use of rescue 
medication and asthma scores were analysed using the 
van Elteren test stratified by centre (12). Logarithmically 
transformed FEV, and FVC values were analysed using 
ANCOVA. Overall scores for therapeutic effect and toler- 
ability were compared between treatments using logistic 
regression. Assessment of therapeutic control was analysed 
using ANCOVA. All statistical tests were two sided and 
carried out at the 5% significance level. 
PATIENTS 
A total of 262 patients were randomized. There were no 
important differences in demographic and baseline data 
between the three treatment groups (Table 1) including 
airway medication, concomitant diseases and other medi- 
cation. Prior to the study 96% of patients were receiving 
short-acting &agonists and 6% were receiving long-acting 
&agonist therapy. Of the patients, 88% were receiving 
inhaled corticosteroids with 11% receiving oral pred- 
nisolone. The study was completed by 198 patients (76%). 
Of the 64 patients who discontinued the study prematurely, 
21 were receiving formoterol 12 pg, 16 were receiving 
formotero124 pg and 27 were receiving salbutamol. Only 14 
patients in total discontinued treatment prematurely owing 
to an adverse event (five on formoterol 12 pg, one on 
formoterol 24 pg and eight on salbutamol). Eight patients 
discontinued treatment due to an unsatisfactory effect (two 
on formoterol 12 pg, two on formoterol 24 pg and four 
on salbutamol). The remaining patients discontinued for 
non-treatment-related reasons. 
PEF 
Formoterol 12 pg and 24 pg produced significantly higher 
morning and evening PEF values during the 3 month study 
period compared with salbutamol (Table 2). There was no 
significant difference between the two doses of formoterol 
with respect to overall morning or evening PEF values. For 
all time points during the week preceding each clinic visit 
both doses of formoterol produced significantly higher 
morning and evening PEF values than salbutamol (Fig. 1 
and Table 3). There were no significant differences between 
formoterol 12 pg and formoterol 24 pg doses. 
RESCUE MEDICATION 
The mean daily number of additional puffs of rescue 
medication was significantlyJower over the study period for 
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TABLE 3. Comparison of PEF values between treatments during the week before examination 
Morning Evening 
Treatment difference Treatment difference 
(1 min- ‘) 95% CI (1 min - ‘) 95% CI 
4 weeks 
F24 vs. Sal 30.6* 15.9-45.3 29.0* 
F12 vs. Sal 26.8* 11.7-41.9 26.5* 
F24 vs. F12 3.8 - 11.1 to 18.7 2.5 
8 weeks 
F24 vs. Sal 32.1* 16.747.5 30.3* 
F12 vs. Sal 38.1* 22.1-54.0 32.2* 
F24 vs. F12 -6 - 21.6 to 9.6 - 1.9 
12 weeks 
F24 vs. Sal 38.9* 22.7-55.1 30.6* 
F12 vs. Sal 37.7* 20.5-54.1 31.9* 
F24 vs. F12 1.6 - 14.8 to 18.1 - 1.4 
*P<O.OOl. F12, formoterol 12 ug; F24, formoterol 24 ug; Sal, salbutamol. 
14.943.1 
12.041.1 
- 11.9 to 16.8 
16444.3 
17.746.8 
- 16.1 to 12.3 
15.046.1 
15.848.1 
- 17.1 to 14.4 
TABLE 4. Mean asthma symptom scores 
Formoterol 12 Formoterol ug 24 ug Salbutamol 400 ug 
(n=76) (n=88) (n=83) 
Day time 0.52 0.37 0.49 
Night-time 0.26 0.22 0.32 
Sleep disturbance 0.27 0.24* 0.33 
*P=O.O6 compared with salbutamol. 
the group receiving formotero124 ug (0.58 puffs) compared 
with those receiving salbutamol (0.85 puffs, P=O.O45). No 
significant difference was seen between formoterol 12 ug 
(0.80 puffs) cmpared with salbutamol. 
ASTHMA SYMPTOM SCORES 
In all three treatment groups there was an improvement in 
mean daytime and night-time asthma scores and mean sleep 
disturbance scores (data not shown). Mean values were 
better in the formotero124 ug group (Table 4. However, no 
differences between the treatments for any of these three 
variables reached statistical significance. 
CLINIC ASSESSMENT OF LUNG FUNCTION 
PEF values measured at 4, 8, and 12 week clinic visits 
showed very similar results to those recorded by the 
patients at home. Significantly higher PEF values were 
seen for formoterol 12 ug and formoterol 24 ug com- 
pared with salbutamol at all clinic visits (PcO.05). There 
were no significant differences between the two doses of 
formoterol. 
At all clinic visits there were no significant differences 
between the three treatment groups with respect to FEV, or 
FVC values (data not shown). 
PATIENTS’ AND INVESTIGATORS OVERALL 
ASSESSMENT OF EFFICACY 
Patients’ assessment of therapeutic effect at the end of the 
study was significantly better for the two formoterol doses 
compared to salbutamol (PcO.02, Table 5). No signifi- 
cant differences between treatments were found for the 
investigators’ assessment of efficacy (data not shown). 
TOLERABILITY 
All three treatments were well tolerated. Formoterol 12 and 
24 ug were both better tolerated than salbutamol with 
respect to the number of patients experiencing drug-related 
adverse events and events leading to discontinuation of 
therapy. Fourteen patients (17%) taking formoterol 12 ug, 
20 patients (22%) taking formoterol 24 ug and 23 patients 
(26%) taking salbutamol experienced drug-related adverse 
events. of these, one patient taking formoterol 12 ug and 
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TABLE 5. Patient assessment of overall therapeutic effect 
Formoterol 12 ug Formoterol 24 ug Salbutamol400 ug 
(n=76) (n=88) (n=83) 
Very good 31 (41%) 30 (34%) 16 (19%) 
Good 22 (29%) 40 (45%) 39 (47%) 
Fair 19 (25%) 16 (18%) 18 (22%) 
Poor 4 (5%) 2 (2%) 10 (12%) 
Sianificant difference between treatments: formoterol 24 ug vs salbutamol, P=O.O02; formoterol 
12-ug vs salbutamol, P=O.O17. 
one patient taking salbutamol experienced events classified 
as serious (chest pain and syncope with supraventricular 
tachycardia, respectively). Only 14 patients in total discon- 
tinued prematurely owing to adverse events. Five patients 
discontinued treatment in the formoterol 12 ug group 
owing to individual cases of depression, malaise, arthralgia, 
bronchitis and asthma. One patient discontinued in the 
formotero124 ug group because of headache. Eight patients 
discontinued in the salbutamol group beadache, chest pain, 
asthma (three), chest infection, tremor, syncope]. No clini- 
cally significant findings were seen over the study period 
with respect to vital signs, laboratory values or ECG 
recordings. Patients’ and investigators’ overall assessment 
of tolerability at the final visit showed no significant 
differences between the three treatments but ‘very good’ 
ratings were more often recorded for formoterol 12 ug 
(41%) and formoterol 24 ug (34%) than for salbutamol 
(19%). 
Discussion 
This study has demonstrated in a group of elderly patients 
with ROAD that the long-acting &agonist formoterol 
when administered by a dry powder inhalation was more 
effective than inhaled salbutamol in improving PEF values. 
The results confirm in an elderly population previously 
reported findings in younger adult asthmatic patients that 
formoterol 12 ug and 24 ug b.i.d. are significantly more 
effective than regular inhaled salbutamol(13,14). The study 
demonstrates that the optimal dose for the elderly is the 
same as for adults (12 ug b.i.d.) as there is no significant 
additional benefit in terms of efficacy for the higher dose, 
24 u,g b.i.d. This does not provide support for the sugges- 
tion that responsiveness to inhaled &agonists declines with 
age (9), which would warrant the use of higher doses. 
This is the first study that has examined the safety and 
tolerability of formoterol dry powder inhalation in an 
elderly population with ROAD. The results show that 
formoterol 12 ug and 24 ug inhaled twice daily from the 
Aeroliser@ is a well-tolerated bronchodilator in the elderly. 
Fewer patients taking formoterol 12 ug experienced drug- 
related adverse reactions compared with formoterol 24 pg, 
suggesting that this dose may be better tolerated overall. 
The use of long-acting &agonists by dry powder inhalation 
may be particularly appropriate in elderly patients because 
of the twice-daily regimen and the ease of use of a breath- 
actuated inhaler. However, data on the use of these drugs in 
the elderly remain limited. 
Regular treatment with long-acting &agonists has been 
reported to cause a reduction in bronchodilator /$-agonist 
responses (15-l 8) and a decrease in the degree of protection 
against exercise (19) and methacholine-induced bronchoc- 
onstriction (15). Our protocol was not designed to investi- 
gate the effects of chronic dosing with formoterol on acute 
bronchodilator and bronchoprotective responses. The 
improvement in PEF values produced by formoterol, how- 
ever, was maintained throughout the 12 weeks of the study. 
In conclusion this study shows that the optimal dose of 
formoterol in the elderly is the same as for other adults. It 
demonstrates that formoterol given by dry powder inhala- 
tion is superior in terms of both efficacy and tolerability 
to salbutamol in the treatment of elderly patients with 
ROAD. 
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